Posted on 11.18.24
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
Posted on 5.8.24
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Posted on 1.15.24
WhiteLab Genomics and Siren Biotechnology Announce Strategic Partnership to Accelerate AI-Powered Advancements in Gene Therapy